These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33766047)

  • 1. Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types.
    Bi G; Liang J; Zheng Y; Li R; Zhao M; Huang Y; Zhan C; Xu S; Fan H
    J Transl Med; 2021 Mar; 19(1):124. PubMed ID: 33766047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics characterization and validation of MSI-related molecular features across multiple malignancies.
    Zheng Y; Huang Y; Bi G; Du Y; Liang J; Zhao M; Chen Z; Zhan C; Xi J; Wang Q
    Life Sci; 2021 Apr; 270():119081. PubMed ID: 33516699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
    Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
    BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancancer network analysis reveals key master regulators for cancer invasiveness.
    Jethalia M; Jani SP; Ceccarelli M; Mall R
    J Transl Med; 2023 Aug; 21(1):558. PubMed ID: 37599366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer characterization of metabolism-related biomarkers identifies potential therapeutic targets.
    Bi G; Bian Y; Liang J; Yin J; Li R; Zhao M; Huang Y; Lu T; Zhan C; Fan H; Wang Q
    J Transl Med; 2021 May; 19(1):219. PubMed ID: 34030708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis identifies telomerase-associated signatures and cancer subtypes.
    Luo Z; Wang W; Li F; Songyang Z; Feng X; Xin C; Dai Z; Xiong Y
    Mol Cancer; 2019 Jun; 18(1):106. PubMed ID: 31179925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.
    Rajamani D; Bhasin MK
    Genome Med; 2016 May; 8(1):38. PubMed ID: 27137215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pan-cancer analysis of driver gene mutations, DNA methylation and gene expressions reveals that chromatin remodeling is a major mechanism inducing global changes in cancer epigenomes.
    Youn A; Kim KI; Rabadan R; Tycko B; Shen Y; Wang S
    BMC Med Genomics; 2018 Nov; 11(1):98. PubMed ID: 30400878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
    Xiao B; Chen L; Ke Y; Hang J; Cao L; Zhang R; Zhang W; Liao Y; Gao Y; Chen J; Li L; Hao W; Sun Z; Li L
    BMC Cancer; 2018 Apr; 18(1):405. PubMed ID: 29642861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
    Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
    Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.
    Hill KE; Kelly AD; Kuijjer ML; Barry W; Rattani A; Garbutt CC; Kissick H; Janeway K; Perez-Atayde A; Goldsmith J; Gebhardt MC; Arredouani MS; Cote G; Hornicek F; Choy E; Duan Z; Quackenbush J; Haibe-Kains B; Spentzos D
    J Hematol Oncol; 2017 May; 10(1):107. PubMed ID: 28506242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of mutations in DNA methylation modification genes on genome-wide methylation landscapes and downstream gene activations in pan-cancer.
    Lee CJ; Ahn H; Jeong D; Pak M; Moon JH; Kim S
    BMC Med Genomics; 2020 Feb; 13(Suppl 3):27. PubMed ID: 32093698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1/CDH1 loop.
    Sengupta D; Deb M; Rath SK; Kar S; Parbin S; Pradhan N; Patra SK
    Exp Cell Res; 2016 Aug; 346(2):176-87. PubMed ID: 27475839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma.
    Singh NP; Vinod PK
    Mol Genet Genomics; 2020 May; 295(3):807-824. PubMed ID: 32185457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computing microRNA-gene interaction networks in pan-cancer using miRDriver.
    Bose B; Moravec M; Bozdag S
    Sci Rep; 2022 Mar; 12(1):3717. PubMed ID: 35260634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer.
    Schmitt K; Molfenter B; Laureano NK; Tawk B; Bieg M; Hostench XP; Weichenhan D; Ullrich ND; Shang V; Richter D; Stögbauer F; Schroeder L; de Bem Prunes B; Visioli F; Rados PV; Jou A; Plath M; Federspil PA; Thierauf J; Döscher J; Weissinger SE; Hoffmann TK; Wagner S; Wittekindt C; Ishaque N; Eils R; Klussmann JP; Holzinger D; Plass C; Abdollahi A; Freier K; Weichert W; Zaoui K; Hess J
    Int J Cancer; 2019 Dec; 145(12):3299-3310. PubMed ID: 31135957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
    Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
    Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic Alternations of MicroRNAs and DNA Methylation Contribute to Liver Metastasis of Colorectal Cancer.
    Liu J; Li H; Sun L; Shen S; Zhou Q; Yuan Y; Xing C
    Dig Dis Sci; 2019 Jun; 64(6):1523-1534. PubMed ID: 30604369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.